The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis
PURPOSE: Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory condition. While few diagnostic scores are established, none exist to predict both clinical course and time-point specific outcome of sHLH patients so far. We present a machine learning (ML)-based tool to predict Initial Disease Severity (IDS; defined as admission to intensive care units (ICU) OR death < 90 days without ICU admission) and mortality across different time points in sHLH patients. METHODS: 167 adult sHLH patients from six study centers across three European countries were included retrospectively. Clinical and demographic features, course, survival, and laboratory data were assessed. Random forest models were trained with two sets of eight clinical and laboratory features: one to predict IDS, and five to predict mortality at distinct time points (30, 60, 90, 180 or 365 days). After calibration, the models were tested against hold-out test sets containing n = 32 (IDS) or n = 43 (mortality) sHLH patients. RESULTS: Overall, the models demonstrated strong discriminatory ability, overall performance, and accurate prediction of risk. Serum levels of the soluble interleukin-2 receptor (sIL-2R) and albumin (for IDS) or sIL-2R and platelet counts (for mortality prediction) showed the strongest contributions to the models' predictions. CONCLUSION: The HLH-Risk-Calculator is an exploratory tool predicting the clinical course of sHLH. External validation is critical to assess its validity, applicability, and robustness for real-world use. To this end, the calculator is available at www.hlh-risk-calculator.com for research use only, and is currently not intended for clinical decision-making.
Authors
- Josia Fauser
- Marion Subklewe (ORCID: https://orcid.org/0000-0001-9154-9469)
- Hans‐Joachim Stemmler (ORCID: https://orcid.org/0000-0001-8751-8555)
- Andreas Pircher (ORCID: https://orcid.org/0000-0002-7747-3012)
- Stephanie-Susanne Stecher (ORCID: https://orcid.org/0000-0001-6715-1020)
- Karsten Spiekermann (ORCID: https://orcid.org/0000-0002-5139-4957)
- Michael von Bergwelt‐Baildon (ORCID: https://orcid.org/0000-0002-1952-052X)
- Clemens‐Martin Wendtner (ORCID: https://orcid.org/0000-0003-2866-2260)
- Hans Stubbe (ORCID: https://orcid.org/0000-0002-7873-996X)
- Michael Medinger (ORCID: https://orcid.org/0000-0003-0427-7747)
- Manuel Trebo (ORCID: https://orcid.org/0000-0001-8597-9729)
- Dominik Wolf
- Katharina Elisabeth Nickel
- Peter Bojko
- Claire Seydoux (ORCID: https://orcid.org/0000-0003-3263-086X)
- Michael Starck
- Thomas Wimmer (ORCID: https://orcid.org/0000-0003-3890-4753)
- Hendrik Schulze‐Koops (ORCID: https://orcid.org/0000-0002-1681-491X)
- Michael Ruzicka (ORCID: https://orcid.org/0000-0002-2451-1070)
- Lena Horvath (ORCID: https://orcid.org/0000-0002-1509-4324)
- Florian Bassermann
- Marcus Hentrich
- F Hauck
- Sabine Janina Ehrlich (ORCID: https://orcid.org/0009-0006-3283-700X)
- Katharina Goetze
Institutions
- Innsbruck Medical University (AT)
- German Cancer Research Center (DE)
- Universität Innsbruck (AT)
- University Hospital of Basel (CH)
- TUM Klinikum (DE)
- LMU Klinikum (DE)
- München Klinik Schwabing (DE)
- Comprehensive Cancer Center Mainfranken (DE)
- German Center for Infection Research (DE)
- München Klinik (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Technical University of Munich (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Intensive Care Medicine
- Published
- 2026-06-30
- DOI
- https://doi.org/10.1007/s00134-026-08515-1
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00